Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
August 27, 2020 07:59 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
March 17, 2020 08:03 ET
|
Cognition Therapeutics, Inc.
New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...